Strategic Operational Redesign Improves Prior Authorization Access: A Validation Study.
approval
independent review organization
prior authorization
proton
radiation
Journal
International journal of particle therapy
ISSN: 2331-5180
Titre abrégé: Int J Part Ther
Pays: United States
ID NLM: 101674108
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
05
2023
accepted:
28
06
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Obtaining prior authorization (PA) before treatment is becoming increasingly burdensome in oncology, especially in radiation oncology. Here, we describe the impact of a strategic novel operational PA redesign to shorten authorization time and to improve patient access to cancer care at a large United States academic proton therapy center. We ask whether such a redesign may be replicable and adoptable across oncology centers. Our PA redesign strategy was based on a 3-tiered approach. Specifically, we (1) held payors accountable to legally backed timelines, (2) leveraged expertise on insurance policies and practices, and (3) updated the submission, appeal writing, and planning procedures for PA. Metrics were compared at the following 3 time points: 6 months before, at phase-in, and at 6 months after intervention. In analyzing the impact of improving PA access to care, the percentage of approvals for commercial proton beam therapy improved by an absolute 30.6% postintervention ( This is the first validated, comprehensive operational strategy to improve access to cancer therapy while reducing the burden of PA. This novel approach may be helpful for addressing barriers to PA in medical and surgical oncology because the redesign is predicated on laws that regulate PA across disciplines.
Identifiants
pubmed: 38075483
doi: 10.14338/IJPT-23-00009.1
pmc: PMC10698628
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65-72Informations de copyright
©Copyright 2023 The Author(s).
Déclaration de conflit d'intérêts
Conflict of Interest: Nancy P. Mendenhall is the Editor-in-Chief of International Journal of Particle Therapy. All other authors declare no conflict of interest.
Références
Adv Radiat Oncol. 2021 Dec 03;7(2):100861
pubmed: 35118213
JCO Oncol Pract. 2020 Oct;16(10):e1067-e1077
pubmed: 32639929
JCO Oncol Pract. 2020 Sep;16(9):e966-e976
pubmed: 32302271
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):724-733
pubmed: 30557675
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):499-508
pubmed: 24798985
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):737-739
pubmed: 31204659
Int J Part Ther. 2021 Jul 27;8(3):36-42
pubmed: 35127974
PLoS One. 2019 Mar 1;14(3):e0213209
pubmed: 30822350
Pract Radiat Oncol. 2020 Sep - Oct;10(5):324-329
pubmed: 31446147
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1496-1504
pubmed: 33677051
JAMA Health Forum. 2021 May 28;2(5):e210859
pubmed: 35977311
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):714-723
pubmed: 30557673